Literature DB >> 33253813

Excess Mortality Associated with Progression Rate in Asymptomatic Aortic Valve Stenosis.

Giovanni Benfari1, Stefano Nistri2, Federico Marin3, Luca F Cerrito3, Luca Maritan3, Elvin Tafciu3, Ilaria Franzese4, Francesco Onorati4, Martina Setti3, Michele Pighi3, Andrea Rossi3, Flavio L Ribichini3.   

Abstract

BACKGROUND: Aortic valve stenosis (AS) is a progressive condition characterized by gradual calcification of the aortic cusps. Progression rate evaluated using echocardiography has been associated with survival. However, data from routine practice covering the whole spectrum of AS severity and the rate of symptom onset are sparse. The aim of this study was to assess outcomes under medical management related to disease progression in asymptomatic patients with a wide range of AS severity.
METHODS: Two hundred twenty-nine consecutive asymptomatic patients (mean age, 77 ± 10 years; 55% men) with AS, preserved left ventricular ejection fraction, and two or more echocardiographic examinations performed from 2004 to 2014 were retrospectively included. The median time between the two echocardiographic examinations was 24 months (interquartile range, 15-46 months). Patients were identified as rapid progressors if the annualized difference in peak aortic velocity between two echocardiographic examinations was ≥0.3 m/sec/y; others were labeled as slow progressors. The primary end point was mortality during medical follow-up (censoring on aortic valve interventions). The secondary end point was overall mortality.
RESULTS: Rapid progressors accounted for 67 of the 229 patients (29%), and this feature was not associated with baseline characteristics. During a median of 5.8 years (interquartile range, 3.4-8.3 years) of follow-up from the first echocardiographic examination, 102 patients (45%) died, 86 (84%) during medical follow-up. Rapid progression rate predicted excess mortality (vs slow progression rate) after adjustment for age, sex, symptoms, baseline left ventricular ejection fraction, and baseline aortic valve area (hazard ratio, 2.50; 95% CI, 1.48-4.21; P = .0006) and after adjusting for peak aortic velocity and left ventricular ejection fraction obtained at the last echocardiographic examination (hazard ratio, 2.07; 95% CI, 1.25-3.46; P = .005). Among patients with baseline peak aortic velocity < 4 m/sec (nonsevere AS), rapid progression rate was associated with higher 5-year mortality compared with slow progression (57% vs 22% [P < .0001] under medical management and 44% vs 18% [P = .005] overall). Outcomes were comparable between nonsevere AS rapid progressors and baseline severe AS. Progression rate showed incremental prognostic value on receiver operating characteristic curve analysis versus AS severity. Of note, among slow progressors, 11 patients (5%) presented with high rates of symptom development and poor outcomes related to ventricular dysfunction or other advanced AS features.
CONCLUSIONS: Progression rate is an individual, almost unpredictable feature among patients with AS. Rapid progression is an incremental marker of excess mortality in asymptomatic patients with AS, independent of clinical and hemodynamic characteristics. Rapid progression rate may identify patients with nonsevere AS at higher risk for events.
Copyright © 2020 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aortic stenosis; Echocardiography; Progression rate; Survival

Year:  2020        PMID: 33253813     DOI: 10.1016/j.echo.2020.11.015

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  4 in total

1.  Association of Annual N-Terminal Pro-Brain Natriuretic Peptide Measurements With Clinical Events in Patients With Asymptomatic Nonsevere Aortic Stenosis: A Post Hoc Substudy of the SEAS Trial.

Authors:  Edina Hadziselimovic; Anders M Greve; Ahmad Sajadieh; Michael H Olsen; Y Antero Kesäniemi; Christoph A Nienaber; Simon G Ray; Anne B Rossebø; Ronnie Willenheimer; Kristian Wachtell; Olav W Nielsen
Journal:  JAMA Cardiol       Date:  2022-04-01       Impact factor: 30.154

2.  ANMCO position paper: 2022 focused update of appropriate use criteria for multimodality imaging: aortic valve disease.

Authors:  Federico Nardi; Paolo Giuseppe Pino; Leonardo De Luca; Carmine Riccio; Manlio Cipriani; Marco Corda; Giuseppina Maura Francese; Domenico Gabrielli; Fabrizio Oliva; Michele Massimo Gulizia; Furio Colivicchi
Journal:  Eur Heart J Suppl       Date:  2022-05-18       Impact factor: 1.624

3.  Impact of sex and sex hormones on pathophysiology and progression of aortic stenosis in a murine model.

Authors:  Marie-Ange Fleury; Mohamed-Salah Annabi; Martine Voisine; Maxime Hervault; Anne-Julie Boilard; Mylène Shen; André Marette; Nancy Côté; Marie-Annick Clavel
Journal:  Physiol Rep       Date:  2022-08

4.  Rapidly progressive aortic stenosis treated with transcatheter aortic valve implantation in a patient with Fabry disease: a case report.

Authors:  María C Saccheri; Tomás F Cianciulli; Federico L Blanco; Rodrigo I Blanco
Journal:  Eur Heart J Case Rep       Date:  2021-06-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.